Advertisement

Reply to: “An individualized cirrhosis screening strategy might be more cost-effective in the general population”

  • Christian Labenz
    Affiliations
    Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany

    Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
    Search for articles by this author
  • Anita Arslanow
    Affiliations
    Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
    Search for articles by this author
  • Frank Lammert
    Affiliations
    Department of Internal Medicine II, University Medical Center Saarland, Homburg, Germany

    Institute for Occupational and Environmental Medicine and Public Health (IAUP), Saarland University, Homburg, Germany

    Hannover Health Science Campus, Hannover Medical School (MHH), Hannover
    Search for articles by this author
  • Peter R. Galle
    Correspondence
    Corresponding author. Address: Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Langenbeckstrasse 1, 55131 Mainz, Germany. Tel.: +49 (0) 6131 17 7275.
    Affiliations
    Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany

    Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
    Search for articles by this author
Published:August 18, 2022DOI:https://doi.org/10.1016/j.jhep.2022.08.006
      We thank Dr. Zhao, Dr. Liao and Dr. Fan for their commentary on our SEAL study funded by the Federal Joint Committee, the highest decision-making body of the self-government of physicians, hospitals and health insurance funds in Germany, and published in the Journal of Hepatology.
      • Labenz C.
      • Arslanow A.
      • Nguyen-Tat M.
      • Nagel M.
      • Worns M.A.
      • Reichert M.C.
      • et al.
      Structured early detection of asymptomatic liver cirrhosis: results of the population-based liver screening program SEAL.
      ,
      • Zhao S.
      • Liao X.
      • Fan R.
      An individualized cirrhosis screening strategy might be more cost-effective in the general population.
      In SEAL (Structured Early detection of Asymptomatic Liver cirrhosis), we were able to demonstrate that screening for cirrhosis and advanced fibrosis in the general population is feasible and that our approach has the potential to increase the early detection rate of these patients.

      Linked Article

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Labenz C.
        • Arslanow A.
        • Nguyen-Tat M.
        • Nagel M.
        • Worns M.A.
        • Reichert M.C.
        • et al.
        Structured early detection of asymptomatic liver cirrhosis: results of the population-based liver screening program SEAL.
        J Hepatol. 2022; 77: 695-701
        • Zhao S.
        • Liao X.
        • Fan R.
        An individualized cirrhosis screening strategy might be more cost-effective in the general population.
        J Hepatol. 2022; 77: 1728-1729https://doi.org/10.1016/j.hep.2022.06.035
        • Kjærgaard M.
        • Lindvig K.P.
        • Hansen J.K.
        • Langkjær Sorensen S.
        • Johansen S.
        • Thorhauge K.
        • et al.
        Does screening for liver fibrosis change alcohol consumption, died, and exercise? A prospective cohort study on the consequences of screening in 2,764 individuals.
        J Hepatol. 2022; 77: S35